fda decision on tirzepatide Allows Compounded During Shortage Review FDA approves new version of

Pham writes that if the FDA follows the committees vote, it could be a transformative first step for mental health care though wont be enough on its own

53 Treatment lengths ranged from 1 to 7 months, with a mean duration of seven weeks to four months until visible clinical improvement was noted

A post-hoc analysis of the SCALE trial showed that liraglutide reduced the apnea-hypopnea index (AHI), a measure of OSA severity, by 12-15 events per hour in patients with moderate-to-severe OSA

For patients with thyroid disease, semaglutide has a longer safety track record in this population compared to tirzepatide, which entered clinical use more recently